Biomarkers in Drug Development (eBook)

MICHAEL R. BLEAVINS, PhD, is cofounder of MichiganTechnology and Research Institute. He retired fromPfizer/Warner-Lambert/Parke-Davis in 2006 and has twenty-threeyears of experience in pharmaceutical research, development, andbiomarkers with more than sixty-five peer-reviewed publications. CLAUDIO CARINI, MD, PhD, FRCPath, is Chief MedicalOfficer and Vice President for Clinical Research at Fresenius.Previously, Claudio served as Global Head of Translational Medicineat MDS and Global Head of Biomarkers at Hoffmann-La Roche. Claudiohas more than twenty years of experience in the field of immunologyand biomarkers and has authored more than 200 publications ininternational and domestic peer-reviewed journals. MALLÉ JURIMA-ROMET, PhD, is Senior Director forDevelopment and Regulatory Services at MDS Pharma Services, whereshe provides strategic and scientific consulting to pharmaceuticaland biotech sponsors, and leads drug development program teams.Mallé has authored over forty peer-reviewed publications andis an adjunct professor at the University of Montreal. RAMIN RAHBARI, MS, is cofounder and Senior Consultant atInnovative Scientific Management. Previously, Ramin has heldpositions at Pfizer, Synaptic, and Parke-Davis pharmaceuticalcompanies, leading cross-functional biomarker teams.

"An extensive index (an estimated 1000 entries), tables, schemes, flow diagrams and color plates (16 pages), as well as good quality paper and a stout binding make this an excellent offering. If you are interested in biomarkers, and it is difficult to imagine anyone reading this who wouldn't be, then this book is for you." (ISSX, 2010)

"I really enjoyed reviewing this book as it is a gem. " (BTS Newsletter, Summer 2010)"[This book] is unquestionably the best available and most updated source of information on the use of biomarkers in Translational Medicine available today. The Editors superbly crafted an excellent resource and straightforward read. ... Aptly described by the editors, biomarkers have emerged as a useful and valuable tool for anyone working in the research and development of novel pharmaceuticals. Replete with case studies, the book demonstrates how biomarkers can improve drug development timelines, lower costs, facilitate better compound selection, reduce late-stage attrition, and open the door to personalized medicine. ... This book is absolutely crucial for drug-development scientists and researchers. Each of the winning chapters has been penned by an official in the relevant field. This is a book that should not be missed by anyone working with biomarkers in the challenging and changing market of today."
--Raffaele Baffa, MD, Translational Sciences, MedImmune, LLC

"The book by Bleavins, et al. is a real tour de force on the topic of biomarkers, and attacks the subject in a well balanced and very holistic way. This is by far the most comprehensive treatise on the topic of biomarkers that has been published to date. The chapters are extremely well written, and it was great fun to read the historical aspects that reminds every reader that biomarkers are not a new invention. Chapters that dwell on the qualification, analytical, and regulatory considerations are very sobering as they show that the use of biomarkers sound easy in theory but considerably more difficult in practice.... The ability of this book to address issues from the scientific to the investment attests to the holistic nature that the editors chose to address in a topic deceptively named with one word...biomarkers. Overall the chapters are evenly informative and consistently well written and organized, which is tribute to the editors.... [A] remarkable aspect of this book is the breadth of experience and diversity of the authors. Rather than maintaining an uniform view from one fraction of the biomarker user world , the editors were broadly inclusive of a wide set of disciplines from academia, pharma industry, and regulatory but also from commercial and laboratory organizations. This diversity brings a richness of experience and knowledge that propels the book to a level of insight that is atypical for a topic of this nature. Another area for which the editors should receive great credit is in the breath of biomarker considerations. The landscape is large and ranges from the more traditional serum analytical assay to the complexities of imaging and genetic biomarkers and the unique issues associated with these fields. Another strength of the book is highlighting examples of the applications of biomarkers in a couple of diseases.... Overall this is an excellent book and will serve as a superb reference for anyone in the field of drug development and translational medicine. It is highly informative, rich in detail and extensive in breath. It deserves to be on the shelf of anyone involved in the discipline of biomarker application. The editors should be commended for having delivered an exceptional piece of work on a very topical issue."
--Diane K. Jorkasky, M.D., Aileron Therapeutics, Inc.